Since many active pharmaceutical ingredients exhibit poor aqueous solubility and bioavailability, there is a need for nanotherapeutics improving their efficacy. Further, smart drug delivery
devices, the nanocarriers, can be utilized to selectively target compounds (e.g. biologics, small molecules) to their site of action by taking advantage of passive accumulation mechanisms or highly
selective carrier-cell interactions.
Our group uses combinations of novel formulation technology and drug release models in order to identify critical quality attributes and process parameters in the manufacture of nanocarrier devices at different scales of production. Further we explore the interplay between manufacturing technology and the in vivo response of nanocarrier formulations applying physiologcally based pharmacokinetic modeling to establish in vitro-in vivo correlations.